Physician profile
Lori Bluvas
NPI 1922026590
$2,490.41
in general payments reported to CMS, 2019-2025
31 companies · $485 in 2025
The $485 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $315 · 2021: $573 · 2022: $500 · 2023: $138 · 2024: $164 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.34 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $246.45 | 2021-2025 | |
| Kaleo, INC. | $125.04 | 2020-2022 | |
| Roche Diagnostics Corporation | $123.75 | 2019-2021 | |
| Bausch Health US, LLC | $121.08 | 2020-2025 | Aplenzin |
| Merck Sharp & Dohme LLC | $114.33 | 2019-2025 | Gardasil 9, Gardasil, Vaxelis |
| Pfizer INC. | $88.38 | 2021-2024 | |
| Urovant Sciences INC | $85.19 | 2022 | |
| Hologic Sales and Service, LLC | $75.38 | 2019-2023 | Aptima, Acessa Provu System |
| Avion Pharmaceuticals | $74.43 | 2021 | |
| Ethicon US, LLC | $70.73 | 2024-2025 | Stratafix |
| Sanofi Pasteur INC. | $70.43 | 2019-2025 | |
| Exact Sciences Corporation | $60.80 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $59.01 | 2023 | Gemtesa |
| Lilly USA, LLC | $53.81 | 2025 | Zepbound |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $48.30 | 2022 | |
| Neurocrine Biosciences, INC. | $42.59 | 2024 | |
| Evofem Biosciences, INC. | $38.47 | 2022 | |
| Sage Therapeutics, LLC | $34.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.26 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $33.37 | 2019-2020 | |
| Seqirus USA INC | $29.25 | 2025 | Flucelvax |
| Boston Scientific Corporation | $25.17 | 2021 | |
| Allergan, INC. | $24.34 | 2022 | |
| Millicent US INC | $23.43 | 2025 | Femlyv |
| Myovant Sciences INC. | $21.65 | 2021 | |
| Octapharma USA, INC. | $21.02 | 2025 | Fibryga |
| Therapeuticsmd, INC. | $18.17 | 2020 | |
| Coloplast Corp | $17.18 | 2020 | |
| Alk-Abello, INC | $16.65 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $15.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Bluvas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.